Pfizer Is Back In The CTLA-4 Game Via Pact With OncoImmune
Executive Summary
Pfizer bought an option to license OncoImmune’s anti-CTLA-4 antibody ONC-392 five years after out-licensing its own internal candidate tremelimumab to AstraZeneca following a study failure.
You may also be interested in...
Deal Watch: Allergan Deal-Binge Includes Derm, NASH Buys
Golden Meditech and MD Anderson establish startup focused on umbilical cord blood-derived T-regulatory therapies. Bayer and Evotec sign their second collaboration in four years, this time focused on renal disease.
Pfizer Oncology Strategy: Keeping Pace In The Doublet/Triplet IO Race
Pfizer has seven immuno-oncology drugs in the clinic and an ambition to be the first drug maker to bring a PD-1/OX40/4-1BB triplet regimen into the clinic late this year or early next.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.